ArticleJournal of robotic surgery2025
Outcomes of robot-assisted partial nephrectomy (RAPN) for cystic renal tumor.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCystic renal tumors (cRT) pose technical challenges during robot-assisted partial nephrectomy (RAPN) due to the risk of cyst rupture, yet their true impact on perioperative outcomes remains unclear. This study aimed to evaluate the surgical and pathological outcomes of RAPN for cRT compared with solid renal tumors (sRT). MATERIALS AND
methodsWe retrospectively analyzed 694 consecutive RAPN cases (2016-2023) at a high-volume center. Tumors were categorized as sRT (n = 609), partially cystic renal tumors with < 50% cystic component (pcRT), and cRT with ≥ 50% cystic component. Patient background, perioperative outcomes, resection techniques, and oncological results were compared. The SIB score was used as a surrogate measure for tumor resection method, distinguishing between enucleation, enucleoresection, and resection.
resultsAmong these 694 cases, 609 (88%), 36 (5%) and 49 (7%) cases were classified into sRT, pcRT and cRT groups, respectively. Age, BMI, RENAL score, or clinical stage showed no differences among the three groups, and tumor size of pcRT and cRT was significantly larger than that of sRT (P = 0.067). No significant differences were observed in operative time, warm ischemia time, blood loss, trifecta achievement, or positive surgical margins. Pathologic up-grade was noted in 28 cases (2.6%) in sRT, while none were noted in pcRT and cRT. Multivariate analysis of predictive factors for WIT, trifecta, and pentafecta, showed that cystic tumor was not identified as predictive factors.
conclusionsRAPN for cystic renal tumors is safe and feasible, with perioperative, pathological, and functional outcomes comparable to solid tumors. The proportion of cystic components did not adversely influence outcomes, supporting the application of standard resection techniques for both cystic and solid tumors. RAPN should be considered a reliable first-line surgical option for cystic tumors when technically feasible.
Indexed as
Identifiers
41264063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.